Keyword: Watson to buy Actavis
News
19.10.2012
- Actavis, the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than €2 billion ($2.6 billion) this year, driven by patent expiries...
News
16.10.2012
- Watson Pharmaceuticals has won U.S. antitrust approval to buy Swiss peer Actavis on the condition that it sell a number of their current and future products to two other companies...
News
12.04.2012
- Watson Pharmaceuticals is on track to announce a deal to buy Actavis for around $6 billion by the end of April, creating one of the world's biggest producers of generic drugs...
